Many studies demonstrate that solid tumors may escape immunosurveillance through upregulation of the IDO1 enzyme in cancer cells and tumor microenvironment, a condition associated with poor clinical outcomes [9,16]. This evidence concerns the gene IDO1 and neoplasm.